OncoMatch/Clinical Trials/NCT04107480
PRolaCT - Three Prolactinoma RCTs
Is NCT04107480 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Dopamine Agonists for prolactinoma.
Treatment: Dopamine Agonists — This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (\>2 years) period of pretreatment with a dopamine agonist is superior to standard care for several outcome parameters. The main objectives are to investigate this for quality of life and remission rate. The secondary objectives are to investigate this for biochemical disease control, recurrence rates, clinical symptom control, tumor shrinkage on MRI, pituitary functioning, the occurrence of adverse reactions to treatment, disease burden, and cost-effectiveness.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: dopamine agonist — PRolaCT-2: 4-6 months; PRolaCT-3: at least 2 years
PRolaCT-2: treatment with a dopamine agonist for 4-6 months; PRolaCT-3: treatment with a dopamine agonist for at least 2 years
Cannot have received: pituitary gland surgery
Prior pituitary gland surgery
Cannot have received: radiotherapy to the pituitary gland area
Prior...radiotherapy to the pituitary gland area
Lab requirements
Kidney function
Severe renal failure (eGFR <30 ml/min) excluded
Severe renal failure (eGFR <30 ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify